UnitedHealth falls on report it secretly paid nursing homes to reduce hospital transfers

UnitedHealth shares fell over 6% after a Guardian report alleged secret payments to nursing homes to reduce hospital transfers, adding to existing pressures from a Change Healthcare cyberattack, probes into company practices, and the CEO's departure. HSBC downgraded UNH to "reduce" with a $270 price target, citing higher medical costs, drug pricing pressure, and potential Medicaid funding cuts as threats to recovery. Despite UnitedHealth's denial and reference to a prior DOJ investigation that closed without action, Wedbush noted the news creates investor uncertainty as Stephen Hemsley returns as CEO to navigate the crisis.

Analysis

UnitedHealth (UNH) shares experienced a significant decline, falling over 6% following a Guardian newspaper report alleging the company made secret payments to nursing homes to reduce hospital transfers as a cost-cutting measure, which reportedly risked resident health. These allegations exacerbate existing pressures on the healthcare conglomerate, which include the fallout from a cyberattack at its Change Healthcare unit, reports of criminal and civil investigations into company practices, and the recent departure of CEO Andrew Witty, who resigned as a director. The company's stock has markedly underperformed, losing more than 39% year-to-date, while the Dow Jones Industrial Average saw a mere 0.6% decrease. UnitedHealth refuted the Guardian's claims, stating that a multi-year U.S. Department of Justice investigation into these specific allegations concluded with the DoJ declining to pursue the matter after finding factual inaccuracies. Despite this defense, investor confidence appears shaken, as highlighted by Wedbush's Sahak Manuelian. Compounding the negative sentiment, HSBC downgraded UNH stock to "reduce" from "hold" and slashed its price target to a street-low of $270, citing concerns over rising medical costs, pressure on drug pricing and its OptumRx pharmacy benefit management unit, and potential Medicaid funding cuts that could hinder recovery. The company has reinstated Stephen Hemsley as CEO, with some market participants, such as Novare Capital Management's James Harlow, expressing hope that his experience will help restore credibility and navigate the current crisis.

Key Decisions for Investors

• Given the heightened uncertainty from multiple negative developments including serious allegations, ongoing investigations, and significant stock underperformance, investors should exercise increased caution with UnitedHealth.
• Closely monitor developments related to the Guardian's allegations, the outcomes of any regulatory probes, the financial and operational impact of the Change Healthcare cyberattack, and the company's ability to manage rising medical costs.
• Consider the recent HSBC downgrade and the $270 price target as a reflection of significant near-term headwinds, and evaluate whether the return of CEO Stephen Hemsley can effectively stabilize the company and restore investor confidence before making investment decisions.